Oncology Archives - Page 3 of 6 - Corcept Therapeutics

ROSELLA (GOG-3073, ENGOT-OV72/MITO): A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Platinum-Resistant Ovarian Cancer

November 6, 2023

Lorusso et al. • 2023 • IGCS 2023 Congress

ROSELLA, GOG‑3073, ENGOT‑OV72/MITO: A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Advanced, Platinum-resistant Ovarian Cancer

October 2, 2023

Lorusso et al. • 2023 • ESGO 2023 Congress

Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

June 27, 2023

Colombo et al. • 2023 • Journal of Clinical Oncology

The glucocorticoid receptor modulator relacorilant reverses the immunosuppressive effects of cortisol

June 6, 2023

Greenstein & Hunt • 2023 • International Immunopharmacology

Selective Glucocorticoid Receptor Modulation Reveals a New Role for CLEC10A in Patients With Solid Tumors

April 17, 2023

Mann et al. • 2023 • AACR 2023

Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators

March 28, 2023

Mallick et al • 2023 • Transl Res.

ROSELLA, GOG‑3073, ENGOT‑OV72/MITO: A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Advanced, Platinum-resistant Ovarian Cancer

March 26, 2023

Alexander Olawaiye et al. • 2023 • SGO Annual Meeting 2023

Phase 1 Efficacy and Pharmacodynamic Results of Exicorilant + Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

February 16, 2023

Michael Morris et al. • 2023 • ASCO GU Cancers Symposium 2023

Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant

February 15, 2023

Pivonello et al • 2022 • Front. Endocrinol.

Phase 2 Results of Relacorilant + Nab-Paclitaxel in Patients with Recurrent, Platinum-resistant Ovarian Cancer with and Without Prior Bevacizumab

February 13, 2023

Colombo et al • 2022 • International Gynecologic Cancer Society 2022 Annual Meeting